In one paragraphArticle in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
18 authors.
Humphrey MulengaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology and Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-2030-0751 Evans MuchiriSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology and Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-4642-2674 Simon C MendelsohnSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology and Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-4054-2766 Stephanus T MalherbeSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0002-7563-8231 Tumelo MoloantoaPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0009-0000-4884-7153 Michele TamerisSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology and Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-7983-7203 Fernanda MaruriVanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-9533-8239 Firdows NoorSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0009-0009-4350-1087 Ravindre PanchiaPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-3601-0839 Khuthadzo HlongwanePerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-0882-9599 Kim StanleySouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0003-4592-2925 Kate HadleySouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology and Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0009-0000-4633-3052 Neil MartinsonPerinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.ORCID 0000-0002-0184-5705 Gerhard WalzlSouth African Medical Research Council Centre for TB Research; Division of Immunology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.ORCID 0000-0003-2487-125X Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology and Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0641-1359 Timothy R SterlingVanderbilt Tuberculosis Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Mark HatherillSouth African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology and Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-3491-1809 RePORT South Africa Study Team
Funding
Evaluation of new diagnostics for incident, active and recurrent TB (ENDx-Tb)U01AI152075 · NIAID · STELLENBOSCH UNIVERSITY · PI BELISLE, JOHN T, SUTHERLAND, JAYNE · 2020 to 2025
$7.1MNIAID NIH HHS U01 AI152075
6 · The paper itselfAbstract
Background: High-risk subgroups among household contacts of persons with tuberculosis (TB) might benefit from additional interventions. However, the significance of an abnormal baseline chest radiograph (CXR) suggestive of TB, despite negative sputum microbiology, is uncertain. Methods: Adults (≥18 years) with recent household TB exposure were enrolled at three South African sites (April 2021-September 2022). All participants underwent symptom screening, CXR, and sputum Xpert Ultra and MGIT culture. Pulmonary TB diagnosis was microbiologically-confirmed. Participants were followed for symptomatic incident TB through 12 months. Multivariable logistic regression identified factors associated with abnormal CXR suggestive of TB. Poisson regression estimated incidence rate ratios (IRR). Results: Baseline CXR were abnormal in 157/795 (19.7%) participants; associated with older age (adjusted odds ratio, aOR=1.04, 95%CI 1.02-1.05); prior TB (aOR=6.39, 95%CI 4.18-9.78); and current smoking (aOR=1.61, 95%CI 1.00-2.62). Symptomatic incident TB developed in 8/795 (1.0%) participants, including 7/8 (87.5%) who were asymptomatic and 4/8 (50.0%) with abnormal CXR at baseline. TB incidence was four-fold higher in those with abnormal versus normal CXR (IRR=4.02, 95%CI 1.01-15.97), with a risk difference of 1,969 (95%CI -657-4,595) per 100,000 person-years, but after median 12.1 (IQR 11.1-13.1) months follow-up, 153/157 (97.5%) had not progressed to incident TB. Conclusions: Adult contacts with CXR abnormalities, but without prevalent TB, had a four-fold higher risk of TB within one year, compared to those with normal CXR. This additional risk warrants targeted preventive treatment and extended surveillance, but since most remained TB-free, therapeutic TB treatment is not justified.
Indexed as
chest radiographhousehold contactincidentrisktuberculosis
Identifiers
PMID42282189
PMCPMC13252466
What Socratic holds
Textmetadata
Read underepoch 390